医学
肺癌
肿瘤科
内科学
突变体
癌症研究
生物化学
基因
化学
作者
Yaxiong Zhang,Zihong Chen,Gang Chen,Yan Huang,Yunpeng Yang,Wenfeng Fang,Li Zhang
标识
DOI:10.1016/j.cllc.2024.06.002
摘要
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significant antitumor activity to advanced non-small-cell lung cancer (NSCLC) patients with classic EGFR mutations. However, EGFR-TKI monotherapy shows poor efficacy in patients whose circulating tumor cell DNA (ctDNA) of EGFR mutations cannot be rapidly cleared.
科研通智能强力驱动
Strongly Powered by AbleSci AI